2018
DOI: 10.1134/s1070428018110015
|View full text |Cite
|
Sign up to set email alerts
|

Cross-Conjugated Cyclopentenone Prostaglandins. Recent Advances

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 16 publications
(2 citation statements)
references
References 95 publications
0
2
0
Order By: Relevance
“…[14,15] This is, e.g. the structural moiety of prostaglandins, [16] that possess potent anti-inflammatory, antineoplastic, and anti-viral activities. [17] Moreover, conjugated cyclopentenones are privileged motifs for anticancer drugs.…”
Section: Resultsmentioning
confidence: 99%
“…[14,15] This is, e.g. the structural moiety of prostaglandins, [16] that possess potent anti-inflammatory, antineoplastic, and anti-viral activities. [17] Moreover, conjugated cyclopentenones are privileged motifs for anticancer drugs.…”
Section: Resultsmentioning
confidence: 99%
“…[3,4] In the past few decades, pharmacologists, medicals and chemists have been showing a steady interest in J-type crossconjugated cyclopentenone prostaglandins (cyPG) that show high and often unique anti-cancer, antiviral, anti-inflammatory, and other properties. [5,6] (Figure 1). For example, 1,15-lactone Δ 12 -PGJ 2 1 is among the most promising cyPGs in the screening against NCI-60 tumor cell lines.…”
Section: Introductionmentioning
confidence: 99%